Company

Pearl Therapeutics

As of the edition of 20 October 2026, Pearl Therapeutics runs 5 drugs; it is on route A at 7 targets and on route B at 0 targets.

Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.

Drugs by status

StatusCount
Went quiet5
Total5

Where it needs a new molecule

Route A at 7 targets, route B at 0 targets.

Three of its 7 rows, by target and route
TargetRoute
ADRB2 Beta-2 adrenergic receptorRoute A
CHRM5 Muscarinic acetylcholine receptor M5Route A
CHRM4 Muscarinic acetylcholine receptor M4Route A

All 7 rows on route A or B

In the product

7 company-target rows on route A or B; 4 are not shown here, and no score is.

Where its trials are

  • Lungs and airways: 9 trials led